These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 33077834)

  • 1. A cell-penetrating MARCKS mimetic selectively triggers cytolytic death in glioblastoma.
    Eustace NJ; Anderson JC; Warram JM; Widden HN; Pedersen RT; Alrefai H; Patel Z; Hicks PH; Placzek WJ; Gillespie GY; Hjelmeland AB; Willey CD
    Oncogene; 2020 Nov; 39(46):6961-6974. PubMed ID: 33077834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
    Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S
    Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myristoylated alanine-rich C-kinase substrate effector domain phosphorylation regulates the growth and radiation sensitization of glioblastoma.
    Eustace NJ; Anderson JC; Langford CP; Trummell HQ; Hicks PH; Jarboe JS; Mobley JA; Hjelmeland AB; Hackney JR; Pedersen RT; Cosby K; Gillespie GY; Bonner JA; Willey CD
    Int J Oncol; 2019 Jun; 54(6):2039-2053. PubMed ID: 30942445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MARCKS regulates growth and radiation sensitivity and is a novel prognostic factor for glioma.
    Jarboe JS; Anderson JC; Duarte CW; Mehta T; Nowsheen S; Hicks PH; Whitley AC; Rohrbach TD; McCubrey RO; Chiu S; Burleson TM; Bonner JA; Gillespie GY; Yang ES; Willey CD
    Clin Cancer Res; 2012 Jun; 18(11):3030-41. PubMed ID: 22619307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.
    McNeill RS; Canoutas DA; Stuhlmiller TJ; Dhruv HD; Irvin DM; Bash RE; Angus SP; Herring LE; Simon JM; Skinner KR; Limas JC; Chen X; Schmid RS; Siegel MB; Van Swearingen AED; Hadler MJ; Sulman EP; Sarkaria JN; Anders CK; Graves LM; Berens ME; Johnson GL; Miller CR
    Neuro Oncol; 2017 Oct; 19(11):1469-1480. PubMed ID: 28379424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug.
    Bi J; Khan A; Tang J; Armando AM; Wu S; Zhang W; Gimple RC; Reed A; Jing H; Koga T; Wong IT; Gu Y; Miki S; Yang H; Prager B; Curtis EJ; Wainwright DA; Furnari FB; Rich JN; Cloughesy TF; Kornblum HI; Quehenberger O; Rzhetsky A; Cravatt BF; Mischel PS
    Cell Rep; 2021 Nov; 37(5):109957. PubMed ID: 34731610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
    Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
    Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alkylaminophenol and GPR17 Agonist for Glioblastoma Therapy: A Combinational Approach for Enhanced Cell Death Activity.
    Doan P; Nguyen P; Murugesan A; Candeias NR; Yli-Harja O; Kandhavelu M
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myristoylated alanine rich protein kinase C substrate is a potential cancer prognostic factor that regulates cell migration and invasion in glioblastoma.
    Xiang W; Peng T; Ming Y; Li S; Wang K; Wang H; Chen L; Zhou J
    Oncol Rep; 2019 Apr; 41(4):2464-2470. PubMed ID: 30816497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of programmed cell death 10 activates tumor cells and leads to temozolomide-resistance in glioblastoma.
    Nickel AC; Wan XY; Saban DV; Weng YL; Zhang S; Keyvani K; Sure U; Zhu Y
    J Neurooncol; 2019 Jan; 141(1):31-41. PubMed ID: 30392087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting PDGFRα-activated glioblastoma through specific inhibition of SHP-2-mediated signaling.
    Sang Y; Hou Y; Cheng R; Zheng L; Alvarez AA; Hu B; Cheng SY; Zhang W; Li Y; Feng H
    Neuro Oncol; 2019 Nov; 21(11):1423-1435. PubMed ID: 31232447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.
    Signore M; Pelacchi F; di Martino S; Runci D; Biffoni M; Giannetti S; Morgante L; De Majo M; Petricoin EF; Stancato L; Larocca LM; De Maria R; Pallini R; Ricci-Vitiani L
    Cell Death Dis; 2014 May; 5(5):e1223. PubMed ID: 24810059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined acetyl-11-keto-β-boswellic acid and radiation treatment inhibited glioblastoma tumor cells.
    Conti S; Vexler A; Edry-Botzer L; Kalich-Philosoph L; Corn BW; Shtraus N; Meir Y; Hagoel L; Shtabsky A; Marmor S; Earon G; Lev-Ari S
    PLoS One; 2018; 13(7):e0198627. PubMed ID: 29969452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the effector domain of the myristoylated alanine rich C-kinase substrate enhances lung cancer radiation sensitivity.
    Rohrbach TD; Jarboe JS; Anderson JC; Trummell HQ; Hicks PH; Weaver AN; Yang ES; Oster RA; Deshane JS; Steele C; Siegal GP; Bonner JA; Willey CD
    Int J Oncol; 2015 Mar; 46(3):1079-88. PubMed ID: 25524703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
    J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ALK inhibitors, alectinib and ceritinib, induce ALK-independent and STAT3-dependent glioblastoma cell death.
    Kawauchi D; Takahashi M; Satomi K; Yamamuro S; Kobayashi T; Uchida E; Honda-Kitahara M; Narita Y; Iwadate Y; Ichimura K; Tomiyama A
    Cancer Sci; 2021 Jun; 112(6):2442-2453. PubMed ID: 33728771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors Influencing the Central Nervous System (CNS) Distribution of the Ataxia Telangiectasia Mutated and Rad3-Related Inhibitor Elimusertib (BAY1895344): Implications for the Treatment of CNS Tumors.
    Rathi S; Mladek AC; Oh JH; Dragojevic S; Burgenske DM; Zhang W; Talele S; Zhang W; Bakken KK; Carlson BL; Connors MA; He L; Hu Z; Sarkaria JN; Elmquist WF
    J Pharmacol Exp Ther; 2024 Oct; 391(2):346-360. PubMed ID: 39284626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme.
    Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P
    J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
    Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
    Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced Anti-Tumor Activity in Mice with Temozolomide-Resistant Human Glioblastoma Cell Line-Derived Xenograft Using SN-38-Incorporated Polymeric Microparticle.
    Yang TC; Liu SJ; Lo WL; Chen SM; Tang YL; Tseng YY
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34074038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.